Rvl Pharmaceuticals plc (RVLPQ)
OTC PINK OTC PINK Primary Summary
Rvl Pharmaceuticals plc (RVLPQ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Rvl Pharmaceuticals plc ever had a stock split?
Rvl Pharmaceuticals plc Profile
| Biotechnology Industry | Healthcare Sector | Brian A. Markison CEO | OTC PINK Exchange | IE00BF2HDL56 ISIN |
| US Country | 125 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
RVL Pharmaceuticals plc operates as a specialty pharmaceutical company focused on the research, development, and commercialization of innovative pharmaceutical products. It primarily serves the ocular and medical aesthetics markets, catering to patient populations that are often underserved in the United States, Argentina, and Hungary. Initially known as Osmotica Pharmaceuticals plc, the company underwent a rebranding in January 2022, adopting the name RVL Pharmaceuticals plc. Its main office is strategically located in Bridgewater, New Jersey, positioning it well to navigate and influence the pharmaceutical industry both domestically and internationally.
Products and Services
- Upneeq (RVL-1201)
An oxymetazoline hydrochloride ophthalmic solution, Upneeq is RVL Pharmaceuticals plc's flagship product, designed specifically for the treatment of acquired blepharoptosis, or low-lying eyelid, in adult patients. This condition, which affects a significant portion of the adult population, leads to reduced visibility and can have a considerable impact on the quality of life. By addressing this particular need, Upneeq represents a significant contribution to the ocular health sector, showcasing RVL Pharmaceuticals plc's commitment to addressing less commonly catered-to health issues through innovative solutions.
